



05-21-04

Docket No.: PF-0425-1 DIV

1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: HUMAN CITRATE SYNTHASE HOMOLOG

Serial No.: 09/996,223

Filing Date: November 27, 2001

Group Art Unit: 1642

---

Commissioner for Patents  
USPTO  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. § 3.73(b),  
REVOCATION OF POWER OF ATTORNEY AND  
APPOINTMENT OF NEW ATTORNEYS

MAY 26 2004

TECH CENTER 1600/2900

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 9108, Frame 0955, hereby revokes all previous powers of attorney and appoints those practitioners under Customer No. 22428 as attorneys/agents with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

Please direct all correspondence to:


Michele M. Simkin, Esq.  
Reg. No. 34,717  
Customer No.: **22428**  
Foley & Lardner LLP  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109

and direct all telephone calls and facsimile transmissions to: Foley & Lardner LLP; Phone:Tel: (202) 672-5300 Fax: (202) 672-5399 The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001, Title 18, of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

INCYTE CORPORATION

Date: April 28 2004

By:   
Patricia Anne Schreck  
Executive VP, General Counsel